Critica: Doriglen Detailing Talk: Doctor, in management of a crisis it is a strong action that goes a long way in providing prolong

assurance of results. Prescribe Doriglen, Doripenem 500 mg inj for prolong assurance. Doriglen reduces endotoxin release as there is 10 fold less Lipo-Poly-Saccharide endotoxin release reported as compared to imipenem & meropenem. Doriglen shows 2.7 times lower endotoxin release as compared to imipenem in gram negative infections. Doriglen shows 6 times lower endotoxin release as compared to meropenem in gram negative infections. Within the carbapenem class, T>MIC is the best predictor of bacterial Killing and stability of Doriglen enhances the opportunity for prolonged infusion regimens & the potential to extend the T>MIC. 4hr infusion of Doripenem provides >90% probability of achieving 35-40% free drug for the exposure time. In critically ill patients prescribe Doriglen, Doripenem 500 mg inj for prolong assurance. Two compact studies & a European study confirmed Doripenem as superior Carbapenem against Gram negative isolates. Doriglen has post antibiotic effect up to 2 hrs. against pseudomonas aeruginosa. Doriglen has low propensity to select resistant pathogens. Doriglen lowers serum endotoxin release & has better stability than other carbapenems. Six pooled phase 3 clinical trials on Doripenem have demonstrated efficacy in serious infections including ventilator associated pneumonia & Narcotizing pancreatitis. Doripenem has also shown its efficacy in eradicating secondary bacteraemia associated with complicated urinary tract infections, complicated intra-abdominal infections, Narcotizing pancreatitis & ventilator associated pneumonia. Doriglen has to be given 500mg TID over 4 hour prolonged infusion.